Department of Otorhinolaryngology, UZ Leuven, Leuven, Belgium; Experimental Otorhinolaryngology, Rhinology Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Lancet Infect Dis. 2022 Aug;22(8):e208-e220. doi: 10.1016/S1473-3099(21)00612-5. Epub 2022 Mar 3.
According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.
根据世界卫生组织的最新报告,抗生素耐药细菌感染的发病率在全球范围内呈上升趋势,导致发病率和死亡率上升,对医疗保健系统的压力也越来越大。然而,新抗生素的开发是一个昂贵且耗时的过程,促使科学家寻求替代抗菌策略。在过去的几十年中,噬菌体(也称为噬菌体)治疗的概念在全球范围内得到了普及。尽管从概念上讲很有前景,但噬菌体治疗在常规临床实践中的广泛实施受到了根据适用临床试验法规的严格标准获得的安全性和疗效数据稀缺的限制。在本次系统评价中,我们列出了 2000 年 1 月 1 日至 2021 年 8 月 14 日期间发表的关于噬菌体治疗治疗难治性细菌感染的安全性和疗效的临床数据,并概述了在多个医学学科中使用噬菌体治疗的试验和案例研究。